SYDNEY, Sept. 29, 2014 /PRNewswire/ -- Novogen Ltd. (ASX:
NRT, NASDAQ: NVGN) CEO & Chairman, Dr Graham Kelly, conducted an interview with ABC TV
that was broadcast on Saturday September
27th during the national 7.00
pm news bulletin and on the following day on Weekend
Breakfast. The interview concerned the Company's efforts in
bringing its drug candidate, Trilexium, into the clinic in
Australia for the treatment of
primary brain cancers such as glioblastoma multiforme.
The interview provides certain new information and is being
announced to the market today for that reason.
The interview discusses the Company's super-benzopyran
anti-cancer drug technology and the collaboration with Yale University that revealed the ability of this
family of molecules to kill cancer stem cells, the cells
responsible for tumor recurrence after radiotherapy and
chemotherapy. Studies then conducted at Weill Cornell Medical
College in New York extended this
finding by identifying a particular molecule with high potency
against glioblastoma cancer stem cells. That molecule has been
formulated into the product, Trilexium, intended to treat cancers
of neural origin including primary brain cancers in adults and
children and neuroblastoma in children.
Sydney-based medical
oncologist, Professor Paul De Souza
of the University of Western
Sydney and Liverpool Hospital, has been appointed Principal
Investigator to conduct a Phase 1 clinical study of Trilexium.
The interview can be found at the following address:
www.novogen.com/news/2014/9/28/ceo-graham-kelly-interview-on-abc-television
About Novogen Limited
Novogen is a public, Australian drug-development company whose
shares trade on both the Australian Securities Exchange ('NRT') and
NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT -- based joint venture company, CanTx Inc,
with Yale University. NOVOGEN LTD
-- ACN 063 259 754 16-20 Edgeworth
David Ave, Hornsby, NSW, 2077 | P: +61 (0) 2 9472 4100
- F: +61 (0) 2 9476 0388 | www.novogen.com
Novogen has two main drug technology platforms:
super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP
compounds have been created to kill the full range of cells within
a tumor, but particularly the cancer stem cells. The ATM compounds
target the microfilament component of the cancer cell and when used
in conjunction with standard anti-microtubular drugs, result in
comprehensive and fatal destruction of the cancer cell's
cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites,
prostate cancer, neural cancers (glioblastoma, neuroblastoma in
children) and melanoma are the key clinical indications being
pursued, with the ultimate objective of employing both technologies
as a unified approach to first-line therapy.
About CanTx
CanTx Inc is a private biotechnology company based in
New Haven, Connecticut, and
established as a joint venture between Novogen and Yale University. CanTx is dedicated to the
development of anti-cancer drugs for the treatment of ovarian
cancer.
Further information is available on the Company's website,
www.novogen.com
And www.can-tx.com
For more information please contact:
Corporate Contact
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2-9472-4100
Media Enquiries
Operations Manager
Novogen Group
Cristyn.Humphreys@novogen.com
+61 (0) 2-9472-4111
Investors Enquiries
Executive Chairman & CEO
Novogen Group
Graham.Kelly@novogen.com
+61 (0) 2-9472-4100
SOURCE Novogen Ltd.